Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Nodus Oncology","sponsor":"Cumulus Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nodus Oncology Launches, Founded by Cumulus Oncology and In Partnership with The Lead Discovery Center, to Focus on Developing First and Best-In-Class Molecules Inhibiting Novel DNA Damage Response Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Nodus Oncology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nodus Oncology Announces Acquisition of Basilea Pharmaceutica\u2019s PARG Inhibitor Programme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Nodus Oncology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"$251.0 million","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Sale of Preclinical Oncology Program to Nodus Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Nodus Oncology","sponsor":"KHAN Technology Transfer Fund I","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Nodus Oncology Secures \u00a32.4m ($2.9m) Investment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Nodus Oncology

    Menu

    Nodus Oncology

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Nodus Oncology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nodus Oncology Secures £2.4m ($2.9m) Investment

              Details:

              With this new funding, Nodus will be able to accelerate the development of its PARG programme in collaboration with the Lead Discovery Center GmbH, continue the development of novel DDR targets and further expand the Company’s portfolio.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: KHAN Technology Transfer Fund I

              Deal Size: $2.9 million Upfront Cash: Undisclosed

              Deal Type: Financing February 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nodus Oncology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nodus Oncology Announces Acquisition of Basilea Pharmaceutica’s PARG Inhibitor Programme

              Details:

              Nodus secures worldwide development and commercialization rights to Basilea’s PARG inhibitor (PARGi) programme – currently at the discovery stage - which has the potential to be a best-in-class treatment for molecularly defined patient sub-groups.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Recipient: Basilea Pharmaceutica

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition September 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nodus Oncology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Basilea Announces Sale of Preclinical Oncology Program to Nodus Oncology

              Details:

              Under the terms of the agreement, Basilea entered into an asset purchase agreement with Nodus Oncology for Basilea’s novel poly (ADP-ribose) glycohydrolase (PARG) inhibitor discovery program.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Recipient: Basilea Pharmaceutica

              Deal Size: $251.0 million Upfront Cash: Undisclosed

              Deal Type: Divestment September 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nodus Oncology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nodus Oncology Launches, Founded by Cumulus Oncology and In Partnership with The Lead Discovery Center, to Focus on Developing First and Best-In-Class Molecules Inhibiting ...

              Details:

              The financing will be used to expand and develop Nodus’ portfolio of first-in-class and best in class assets. LDC will act as the drug discovery arm of Nodus and participate in the development of all assets in Nodus’ pipeline.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cumulus Oncology

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing September 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY